Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.

Vizamyl is now additionally indicated for use in a selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information.

All 3 doses of orforglipron superior to placebo with respect to primary end point of change in HbA1c from baseline to week 40.

Researchers found that at week 24, 81 and 16% of the treated and control wounds, respectively, were at least 50% healed from baseline.